ABCureD wins 1st place for Innovative Biotech Startup at HBIO

ABCURED wins 1st award for most innovative startup 2023

The 3rd Forum of The Hellenic Bio Cluster closed with a bang. For 3 days it brought the technology, science, production and entrepreneurship fields of the Balkan health sciences cluster onto center stage.

ABCureD had the honor to win 1st place for most Innovative Biotech Startup at the forum’s competition. Dr. Akaterini Alexiou-Hatzaki, Professor of Pharmacology at the Democritus University of Thrace, was awarded the first prize on behalf of the company.

ABCureD won for having developed an original cutting edge method —the only one of it’s kind internationally— which can detect pancreatic decline making it a valuable clinical tool for the timely diagnosis of diabetes and personalization of the illnesses management. Even help prevent the development of diabetes in pre diabetic patients.

ABCureD P.C. is a spinoff company of Democritus University of Thrace in the biotech sector. Using state of the art AutoML and an innovative minimally invasive method called Liquid Biopsy it can discover novel Biomarkers that affect diseases like diabetes, making it possible to provide better treatment to each patient.

The Hellenic BioCluster organized its 3rd Forum on the subject of “Supporting disruptive innovation to maximize the economic and social impact of the bio-industry sector”, held between 15 – 17 June 2023 at Megaron Athens International Conference Centre, Athens, Greece.

The 3rd HBio Forum featured a 3-day, cutting-edge programme with inspiring speakers from across the globe, all experts in disruptive innovation, with the aim to connect the global biotech innovation community under the sunny Athens skies.

Elevate Greece was the official sponsor of the Forum.

Traction & achievements

An EPO/WIPO patent application has been filed and is currently under consideration, entitled ‘Method for monitoring pancreatic beta-cell destruction in disease prediction/diagnosis/prognosis of type 2 Diabetes Mellitus’ (EP21386030, PCT/EP2022/000048 filing date 20/5/2022). Initial EPO feedback was positive.

Team & Why Us

Ekaterini Alexiou – Chatzaki PhD, CEO & Co-founder, Professor of Pharmacology, Faculty of Medicine, Democritus University of Thrace (Med-DUTH). Director, Research Institute Agro-Health, Hellenic Mediterranean University, Crete. Strong background in biomarker discovery & novel therapeutic targets, EPO/PCT patent owner.

Theodoros Constantinidis, COO & Co-founder Occupational Physician, Professor of Hygiene, Director of the Laboratory of Hygiene and Environmental Protection, Med-DUTH. Editor of the scientific journal Hygeia@ergasia. Chairman of the Standing Committee for Hazardous Occupations. Chairman of the National Examination Committee for the Specialization of Occupational Medicine.

Theodosios Theodosiou, CTO & Co-founder – PhD Bioinformatics. Digital technology entrepreneur, Founder of the Statnous startup, Researcher in EnzyQuest’s startup Bioinformatics Research Department. Data Protection Officer (DPO) experience.

Maria Christina Cheimonidi, CSO & Co-founder – Msc, PhD Molecular Biology. Post Doctoral Researcher, Institute of Molecular Biology & Biotechnology (IMBB-FORTH), Greece. External research collaborator in the Institute of Agro-Health. IKY fellowship grantee for PhD research.

SHARE ON:

Facebook
Twitter
LinkedIn
LIFO interview with Dr. Ekaterini Chatzaki

LIFO Podcast Interview

Professor Ekaterini Alexiou-Chatzaki discusses ABCureD’s success, at the NBG Seed Awards, with Ioannis Pantazopoulos, host of the RADIO Lifo podcast. The topic was Health & Innovation: the people behind the succesful startups.

Read More »
Professor E. Chatzakis interview for EURO2day

Prof. E. Chatzaki Interviewed about LPancreas by EURO2day

Prof. Ekaterini Chatzaki, CEO and coFounder of ABCURED, was interviewed by Maria Moschou for the Greek online media EURO2day regarding the recent first award received at the NBG (National Bank Greece) Seed Awards, for our innovative first diabetes prediction product, LPancreas.

Read More »